文献速递肝病

格卡瑞韦/哌仑他韦治疗慢性HCV感染的真实世界有效性与安全性:荟萃分析

Real-world effectiveness and safety of glecaprevir/pibrentasvir for the treatment of patients with chronic HCV infection: A meta-analysis.
PubMed 文献 · J Hepatol · 2020-02-13

该荟萃分析纳入18项真实世界研究、12,531例接受格卡瑞韦/哌仑他韦治疗的慢性HCV感染成人,汇总分析显示ITT人群SVR12为96.7%(95%CI 95.4-98.1),mITT人群为98.1%(95%CI 97.1-99.2),安全性良好。

要点

  • 真实世界中格卡瑞韦/哌仑他韦治疗慢性HCV的SVR12在ITT人群达96.7%,mITT人群达98.1%。
  • 各亚组(基因型、肝硬化状态、治疗史、疗程等)SVR12率均≥95%。
  • 不良事件报告率17.7%,严重不良事件1.0%,因不良事件停药0.6%。

核心结论

  • 真实世界证据表明格卡瑞韦/哌仑他韦是一种耐受性良好且高度有效的泛基因型HCV治疗方案,覆盖广泛患者人群。

研究设计与样本

  • 系统综述与荟萃分析,检索2017年1月1日至2019年2月25日期刊文献及截至2019年4月14日会议报告的真实世界研究。
  • 纳入报告成人HCV感染(n≥20)接受格卡瑞韦/哌仑他韦治疗且报告SVR12的真实世界研究,共18个队列、12,531例成人。
  • 采用随机效应荟萃分析计算SVR12率(使用≥2个队列的数据),ITT分析纳入有SVR12数据、早期停药或失访的患者,mITT分析排除非病毒学失败者;不良事件率采用朴素合并计算。

主要发现

  • ITT人群(n=8,583,15个队列)SVR12率为96.7%(95%CI 95.4-98.1)。
  • mITT人群(n=7,001,14个队列)SVR12率为98.1%(95%CI 97.1-99.2)。
  • 各亚组(HCV基因型、肝硬化状态、治疗史、治疗时长、说明书内治疗及关注亚组)SVR12率均≥95%。
  • 不良事件报告率为17.7%(1,271/7,199,8个队列),严重不良事件为1.0%(55/5,522,6个队列)。
  • 最常见不良事件为瘙痒、疲劳和头痛;因不良事件停药率为0.6%(33/5,595,6个队列)。

关键数值与推荐

  • ITT人群SVR12率96.7%(95%CI 95.4-98.1)。
  • mITT人群SVR12率98.1%(95%CI 97.1-99.2)。
  • 不良事件率17.7%,严重不良事件率1.0%,因不良事件停药率0.6%。

临床怎么用

  • 真实世界数据支持格卡瑞韦/哌仑他韦作为慢性HCV感染(基因型1-6)成人的高效泛基因型治疗选择。
  • 各亚组(包括肝硬化、经治、不同疗程等)SVR12率均≥95%,支持在常规临床实践中广泛使用。
  • 不良事件率较低、因不良事件停药率仅0.6%,提示该方案耐受性良好,适合多样化患者人群。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Glecaprevir/pibrentasvir is approved for treating adults infected with HCV genotypes 1-6. In clinical trials, glecaprevir/pibrentasvir was associated with high rates of sustained virologic response at post-treatment week 12 (SVR12) and was well tolerated. A systematic review and meta-analysis of the real-world effectiveness and safety of glecaprevir/pibrentasvir were undertaken. METHODS: Real-world studies reporting SVR12 in adults with HCV infection (n ≥20) treated with glecaprevir/pibrentasvir were identified in journal publications from January 1, 2017, to February 25, 2019, and congress presentations through April 14, 2019. Random-effects meta-analysis was used to determine SVR12 rates using data from ≥2 cohorts; intention-to-treat (ITT) analyses included patients treated with glecaprevir/pibrentasvir who had SVR12 data available, discontinued early, or were lost to follow-up; modified ITT (mITT) analyses excluded those with non-virologic failure. Naïve pooling was used to calculate adverse event (AE) rates. RESULTS: Overall, 12,531 adults were treated with glecaprevir/pibrentasvir (18 cohorts). Of patients with post-treatment week 12 data, SVR12 rates were 96.7% (95% CI 95.4-98.1) in the ITT population (n = 8,583, 15 cohorts) and 98.1% (95% CI 97.1-99.2) in the mITT population (n = 7,001, 14 cohorts). SVR12 rates were ≥95% across subgroups (HCV genotype, cirrhosis status, treatment history, treatment duration, on-label treatment, and subgroups of interest). AEs were reported in 17.7% (1,271/7,199) of patients (8 cohorts). Serious AEs were reported in 1.0% (55/5,522) of patients (6 cohorts). The most frequent AEs were pruritus, fatigue, and headache. AE-related treatment discontinuations were reported in 0.6% (33/5,595) of patients (6 cohorts). CONCLUSIONS: Consistent with clinical trials, real-world evidence indicates that glecaprevir/pibrentasvir is a well-tolerated and highly effective pangenotypic treatment for a broad range of HCV-infected patients. LAY SUMMARY: It is important to assess treatments for hepatitis C virus (HCV) in the real world, as patient populations tend to be more diverse and potentially less adherent to treatment compared to those in clinical trials. Results from 18 studies performed in real-world clinics were pooled and analyzed to investigate the effectiveness and safety of a direct-acting antiviral combination (glecaprevir/pibrentasvir) in routine clinical practice. This analysis showed that glecaprevir/pibrentasvir is highly effective and well tolerated across all HCV genotypes and patient groups studied. It also showed that results seen in the real world are similar to the results seen in clinical trials, even in patients historically considered more challenging to treat.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Lampertico P, Carrión JA, Curry M, et al. Real-world effectiveness and safety of glecaprevir/pibrentasvir for the treatment of patients with chronic HCV infection: A meta-analysis. J Hepatol. 2020. PMID: 32061651. doi:10.1016/j.jhep.2020.01.025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。